Trade

with

Progenics Pharmaceuticals Inc
(NASDAQ: PGNX)
AdChoices
4.72
+0.11
+2.39%
After Hours :
4.72
0.00
0.00%

Open

4.53

Previous Close

4.61

Volume (Avg)

764.00k (902.55k)

Day's Range

4.50-4.73

52Wk Range

3.10-7.45

Market Cap.

328.30M

Dividend Rate ( Yield )

-

Beta

1.53

Shares Outstanding

69.56M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 7.86M

    • Net Income

    • -42.57M

    • Market Cap.

    • 328.30M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -553.35

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.53

    • Forward P/E

    • -6.74

    • Price/Sales

    • 42.19

    • Price/Book Value

    • 3.34

    • Price/Cash flow

    • -8.15

      • EBITDA

      • -42.04M

      • Return on Capital %

      • -30.41

      • Return on Equity %

      • -41.62

      • Return on Assets %

      • -30.41

      • Book Value/Share

      • 1.41

      • Shares Outstanding

      • 69.56M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 11.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.69

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -18.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -34.98

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 91.33

            • 82.75

            • Pre-Tax Margin

            • -558.44

            • 39.38

            • Net Profit Margin

            • -553.35

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 96.90

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -344.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 20.39

              • 2.92

              • Quick Ratio

              • 19.95

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.35

              • 2.21

              • Book Value/Share

              • 1.41

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.57

                • 217.39

                • P/E Ratio 5-Year High

                • -18.34

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.28

                • 124.82

                • Price/Sales Ratio

                • 41.84

                • 9.52

                • Price/Book Value

                • 3.31

                • 8.61

                • Price/Cash Flow Ratio

                • -8.15

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -41.62

                        (-41.50)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -30.41

                        (-35.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -41.62

                        (-41.50)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.05

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -42.98M
                      Operating Margin
                      -546.68
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -8.15
                      Ownership

                      Institutional Ownership

                      75.28%

                      Top 10 Institutions

                      60.39%

                      Mutual Fund Ownership

                      39.62%

                      Float

                      80.32%

                      5% / Insider Ownership

                      2.30%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Kaufmann Fund

                      •  

                        9,211,000

                      • 0.00

                      • 13.24

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        4,065,966

                      • 0.00

                      • 5.85

                      • AST Federated Aggressive Growth

                      •  

                        2,134,690

                      • 0.00

                      • 3.07

                      • Federated Kaufmann Small Cap Fund

                      •  

                        1,958,600

                      • -2.79

                      • 2.82

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,170,474

                      • 0.00

                      • 1.68

                      • iShares Russell 2000 (AU)

                      •  

                        1,041,619

                      • -1.46

                      • 1.33

                      • iShares Nasdaq Biotechnology

                      •  

                        899,817

                      • -0.47

                      • 1.15

                      • Vanguard Extended Market Index Fund

                      •  

                        657,580

                      • 4.35

                      • 0.95

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        607,944

                      • 0.00

                      • 0.87

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Global Inv Mgmt Corp

                      •  

                        13,508,290

                      • +532.80%

                      • 19.42

                      • Broadfin Capital, LLC

                      •  

                        8,951,169

                      • +145.13%

                      • 12.87

                      • Baker Bros Advisors LLC

                      •  

                        4,449,797

                      • 0.00%

                      • 6.40

                      • Fidelity Management and Research Company

                      •  

                        4,076,046

                      • -7.49%

                      • 5.86

                      • BlackRock Fund Advisors

                      •  

                        2,594,840

                      • -6.03%

                      • 3.73

                      • Tudor Investment Corp Et AL

                      •  

                        2,342,388

                      • 0.00%

                      • 3.37

                      • Vanguard Group, Inc.

                      •  

                        1,921,462

                      • +3.54%

                      • 2.76

                      • Highland Capital Management L.P.

                      •  

                        1,591,528

                      • +15.02%

                      • 2.29

                      • Wellington Management Company, LLP

                      •  

                        1,569,104

                      • +1.52%

                      • 2.26

                      • State Street Corp

                      •  

                        995,936

                      • +0.15%

                      • 1.43

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidat...morees are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase ...more2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.lessless

                      Key People

                      Mr. Mark R. Baker

                      CEO/Director/President

                      Dr. Paul J. Maddon

                      Director/Founder/Vice Chairman of the Board

                      Mr. Peter J. Crowley

                      Chairman of the Board/Director

                      Mr. Angelo W. Lovallo, Jr

                      CFO/Chief Accounting Officer/Treasurer/Vice President, Divisional

                      Dr. Robert J. Israel,M.D.

                      Executive VP, Divisional

                      • Progenics Pharmaceuticals Inc

                      • 777 Old Saw Mill River Road

                      • Tarrytown, NY 10591

                      • USA.Map

                      • Phone: +1 914 789-2800

                      • Fax: +1 914 789-2817

                      • progenics.com

                      Incorporated

                      1988

                      Employees

                      69

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: